nodes	percent_of_prediction	percent_of_DWPC	metapath
Captopril—MMP2—liver cancer	0.274	0.371	CbGaD
Captopril—F2—liver cancer	0.235	0.317	CbGaD
Captopril—MMP9—liver cancer	0.181	0.244	CbGaD
Captopril—ALB—liver cancer	0.0502	0.0679	CbGaD
Captopril—REN—posterior vena cava—liver cancer	0.0247	0.263	CbGeAlD
Captopril—F2—posterior vena cava—liver cancer	0.0172	0.183	CbGeAlD
Captopril—F2—hepatic artery—liver cancer	0.0152	0.162	CbGeAlD
Captopril—F2—portal vein—liver cancer	0.0132	0.14	CbGeAlD
Captopril—ACE—umbilical vein—liver cancer	0.00337	0.0358	CbGeAlD
Captopril—MMP2—gall bladder—liver cancer	0.00299	0.0318	CbGeAlD
Captopril—LTA4H—embryo—liver cancer	0.00267	0.0284	CbGeAlD
Captopril—F2—gall bladder—liver cancer	0.00227	0.0241	CbGeAlD
Captopril—MMP2—embryo—liver cancer	0.0019	0.0202	CbGeAlD
Captopril—Aphthous stomatitis—Sorafenib—liver cancer	0.0019	0.0313	CcSEcCtD
Captopril—Nephrotic syndrome—Sorafenib—liver cancer	0.00184	0.0304	CcSEcCtD
Captopril—MMP9—embryo—liver cancer	0.00165	0.0175	CbGeAlD
Captopril—ALB—gall bladder—liver cancer	0.00145	0.0154	CbGeAlD
Captopril—LTA4H—liver—liver cancer	0.00124	0.0131	CbGeAlD
Captopril—Tubulointerstitial nephritis—Sorafenib—liver cancer	0.00116	0.0192	CcSEcCtD
Captopril—Proteinuria—Sorafenib—liver cancer	0.00101	0.0167	CcSEcCtD
Captopril—Protein urine present—Sorafenib—liver cancer	0.000997	0.0165	CcSEcCtD
Captopril—Glossitis—Sorafenib—liver cancer	0.000964	0.0159	CcSEcCtD
Captopril—Drug interaction—Sorafenib—liver cancer	0.000958	0.0158	CcSEcCtD
Captopril—REN—liver—liver cancer	0.000955	0.0101	CbGeAlD
Captopril—Anuria—Epirubicin—liver cancer	0.00094	0.0155	CcSEcCtD
Captopril—Blood pressure increased—Sorafenib—liver cancer	0.000889	0.0147	CcSEcCtD
Captopril—ACE—embryo—liver cancer	0.00088	0.00935	CbGeAlD
Captopril—MMP2—liver—liver cancer	0.000878	0.00932	CbGeAlD
Captopril—Anuria—Doxorubicin—liver cancer	0.00087	0.0144	CcSEcCtD
Captopril—Gynaecomastia—Sorafenib—liver cancer	0.000795	0.0131	CcSEcCtD
Captopril—MMP9—liver—liver cancer	0.000763	0.00811	CbGeAlD
Captopril—Aphthous stomatitis—Epirubicin—liver cancer	0.0007	0.0116	CcSEcCtD
Captopril—Renal failure acute—Sorafenib—liver cancer	0.000699	0.0116	CcSEcCtD
Captopril—Dermatitis exfoliative—Sorafenib—liver cancer	0.000684	0.0113	CcSEcCtD
Captopril—F2—liver—liver cancer	0.000666	0.00708	CbGeAlD
Captopril—Aphthous stomatitis—Doxorubicin—liver cancer	0.000648	0.0107	CcSEcCtD
Captopril—Hyponatraemia—Sorafenib—liver cancer	0.000648	0.0107	CcSEcCtD
Captopril—SLC15A1—liver—liver cancer	0.000567	0.00603	CbGeAlD
Captopril—Pancreatitis—Sorafenib—liver cancer	0.000547	0.00904	CcSEcCtD
Captopril—Myasthenia—Epirubicin—liver cancer	0.000523	0.00864	CcSEcCtD
Captopril—Neutropenia—Sorafenib—liver cancer	0.000521	0.00862	CcSEcCtD
Captopril—Erectile dysfunction—Sorafenib—liver cancer	0.000514	0.00849	CcSEcCtD
Captopril—Weight decreased—Sorafenib—liver cancer	0.000504	0.00834	CcSEcCtD
Captopril—Stevens-Johnson syndrome—Sorafenib—liver cancer	0.000493	0.00815	CcSEcCtD
Captopril—Renal failure—Sorafenib—liver cancer	0.000489	0.00808	CcSEcCtD
Captopril—Stomatitis—Sorafenib—liver cancer	0.000485	0.00801	CcSEcCtD
Captopril—Jaundice—Sorafenib—liver cancer	0.000485	0.00801	CcSEcCtD
Captopril—Myasthenia—Doxorubicin—liver cancer	0.000483	0.00799	CcSEcCtD
Captopril—Blister—Epirubicin—liver cancer	0.000456	0.00753	CcSEcCtD
Captopril—ALB—liver—liver cancer	0.000425	0.00452	CbGeAlD
Captopril—Erythema multiforme—Sorafenib—liver cancer	0.000422	0.00698	CcSEcCtD
Captopril—Blister—Doxorubicin—liver cancer	0.000422	0.00697	CcSEcCtD
Captopril—Necrosis—Epirubicin—liver cancer	0.000418	0.00692	CcSEcCtD
Captopril—Flushing—Sorafenib—liver cancer	0.000414	0.00685	CcSEcCtD
Captopril—ACE—liver—liver cancer	0.000407	0.00432	CbGeAlD
Captopril—Ageusia—Epirubicin—liver cancer	0.000405	0.0067	CcSEcCtD
Captopril—Alopecia—Sorafenib—liver cancer	0.000394	0.00652	CcSEcCtD
Captopril—Liver injury—Epirubicin—liver cancer	0.00039	0.00645	CcSEcCtD
Captopril—Necrosis—Doxorubicin—liver cancer	0.000387	0.0064	CcSEcCtD
Captopril—Dysgeusia—Sorafenib—liver cancer	0.00038	0.00629	CcSEcCtD
Captopril—Ageusia—Doxorubicin—liver cancer	0.000375	0.0062	CcSEcCtD
Captopril—Jaundice cholestatic—Epirubicin—liver cancer	0.000374	0.00618	CcSEcCtD
Captopril—Liver injury—Doxorubicin—liver cancer	0.000361	0.00597	CcSEcCtD
Captopril—Anaemia—Sorafenib—liver cancer	0.000359	0.00594	CcSEcCtD
Captopril—Oliguria—Epirubicin—liver cancer	0.000356	0.00589	CcSEcCtD
Captopril—Glossitis—Epirubicin—liver cancer	0.000356	0.00589	CcSEcCtD
Captopril—Angioedema—Sorafenib—liver cancer	0.000355	0.00587	CcSEcCtD
Captopril—Syncope—Sorafenib—liver cancer	0.000348	0.00576	CcSEcCtD
Captopril—Ulcer—Epirubicin—liver cancer	0.000347	0.00574	CcSEcCtD
Captopril—Jaundice cholestatic—Doxorubicin—liver cancer	0.000346	0.00572	CcSEcCtD
Captopril—Loss of consciousness—Sorafenib—liver cancer	0.000341	0.00564	CcSEcCtD
Captopril—Cough—Sorafenib—liver cancer	0.000339	0.0056	CcSEcCtD
Captopril—Arthralgia—Sorafenib—liver cancer	0.000331	0.00547	CcSEcCtD
Captopril—Myalgia—Sorafenib—liver cancer	0.000331	0.00547	CcSEcCtD
Captopril—Oliguria—Doxorubicin—liver cancer	0.00033	0.00545	CcSEcCtD
Captopril—Glossitis—Doxorubicin—liver cancer	0.00033	0.00545	CcSEcCtD
Captopril—Hepatocellular injury—Epirubicin—liver cancer	0.000328	0.00543	CcSEcCtD
Captopril—Dry mouth—Sorafenib—liver cancer	0.000323	0.00535	CcSEcCtD
Captopril—Hyperkalaemia—Epirubicin—liver cancer	0.000323	0.00533	CcSEcCtD
Captopril—Ulcer—Doxorubicin—liver cancer	0.000321	0.00531	CcSEcCtD
Captopril—Anaphylactic shock—Sorafenib—liver cancer	0.000317	0.00524	CcSEcCtD
Captopril—Shock—Sorafenib—liver cancer	0.000312	0.00516	CcSEcCtD
Captopril—Thrombocytopenia—Sorafenib—liver cancer	0.00031	0.00513	CcSEcCtD
Captopril—ABCB1—embryo—liver cancer	0.00031	0.00329	CbGeAlD
Captopril—Hepatocellular injury—Doxorubicin—liver cancer	0.000304	0.00502	CcSEcCtD
Captopril—Dry eye—Epirubicin—liver cancer	0.000303	0.00501	CcSEcCtD
Captopril—Anorexia—Sorafenib—liver cancer	0.000302	0.005	CcSEcCtD
Captopril—Hyperkalaemia—Doxorubicin—liver cancer	0.000299	0.00494	CcSEcCtD
Captopril—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000289	0.00478	CcSEcCtD
Captopril—Dyspnoea—Sorafenib—liver cancer	0.000283	0.00467	CcSEcCtD
Captopril—Dry eye—Doxorubicin—liver cancer	0.000281	0.00464	CcSEcCtD
Captopril—Lymphadenopathy—Epirubicin—liver cancer	0.000279	0.00462	CcSEcCtD
Captopril—Dyspepsia—Sorafenib—liver cancer	0.000279	0.00461	CcSEcCtD
Captopril—Decreased appetite—Sorafenib—liver cancer	0.000276	0.00456	CcSEcCtD
Captopril—Diabetes mellitus—Epirubicin—liver cancer	0.000274	0.00453	CcSEcCtD
Captopril—Fatigue—Sorafenib—liver cancer	0.000273	0.00452	CcSEcCtD
Captopril—Photosensitivity—Epirubicin—liver cancer	0.000272	0.00449	CcSEcCtD
Captopril—Constipation—Sorafenib—liver cancer	0.000271	0.00448	CcSEcCtD
Captopril—Gastrointestinal pain—Sorafenib—liver cancer	0.000259	0.00429	CcSEcCtD
Captopril—Lymphadenopathy—Doxorubicin—liver cancer	0.000259	0.00427	CcSEcCtD
Captopril—Renal failure acute—Epirubicin—liver cancer	0.000258	0.00427	CcSEcCtD
Captopril—Diabetes mellitus—Doxorubicin—liver cancer	0.000254	0.00419	CcSEcCtD
Captopril—Dermatitis exfoliative—Epirubicin—liver cancer	0.000253	0.00418	CcSEcCtD
Captopril—Photosensitivity—Doxorubicin—liver cancer	0.000251	0.00415	CcSEcCtD
Captopril—Body temperature increased—Sorafenib—liver cancer	0.000251	0.00414	CcSEcCtD
Captopril—Abdominal pain—Sorafenib—liver cancer	0.000251	0.00414	CcSEcCtD
Captopril—Dermatitis bullous—Epirubicin—liver cancer	0.000249	0.00412	CcSEcCtD
Captopril—Anaphylactoid reaction—Epirubicin—liver cancer	0.000246	0.00407	CcSEcCtD
Captopril—Cerebrovascular accident—Epirubicin—liver cancer	0.000243	0.00402	CcSEcCtD
Captopril—Hyponatraemia—Epirubicin—liver cancer	0.000239	0.00396	CcSEcCtD
Captopril—Renal failure acute—Doxorubicin—liver cancer	0.000239	0.00395	CcSEcCtD
Captopril—Dermatitis exfoliative—Doxorubicin—liver cancer	0.000234	0.00386	CcSEcCtD
Captopril—Dermatitis bullous—Doxorubicin—liver cancer	0.000231	0.00382	CcSEcCtD
Captopril—Anaphylactoid reaction—Doxorubicin—liver cancer	0.000228	0.00377	CcSEcCtD
Captopril—Asthenia—Sorafenib—liver cancer	0.000227	0.00376	CcSEcCtD
Captopril—Cardiac arrest—Epirubicin—liver cancer	0.000227	0.00375	CcSEcCtD
Captopril—Cerebrovascular accident—Doxorubicin—liver cancer	0.000225	0.00372	CcSEcCtD
Captopril—Pruritus—Sorafenib—liver cancer	0.000224	0.00371	CcSEcCtD
Captopril—Ataxia—Epirubicin—liver cancer	0.000224	0.00371	CcSEcCtD
Captopril—Hyponatraemia—Doxorubicin—liver cancer	0.000221	0.00366	CcSEcCtD
Captopril—Orthostatic hypotension—Epirubicin—liver cancer	0.000218	0.0036	CcSEcCtD
Captopril—Diarrhoea—Sorafenib—liver cancer	0.000217	0.00359	CcSEcCtD
Captopril—Muscular weakness—Epirubicin—liver cancer	0.00021	0.00348	CcSEcCtD
Captopril—Cardiac arrest—Doxorubicin—liver cancer	0.00021	0.00347	CcSEcCtD
Captopril—Dizziness—Sorafenib—liver cancer	0.00021	0.00347	CcSEcCtD
Captopril—Ataxia—Doxorubicin—liver cancer	0.000207	0.00343	CcSEcCtD
Captopril—Eosinophilia—Epirubicin—liver cancer	0.000204	0.00337	CcSEcCtD
Captopril—Pancreatitis—Epirubicin—liver cancer	0.000202	0.00334	CcSEcCtD
Captopril—Vomiting—Sorafenib—liver cancer	0.000202	0.00333	CcSEcCtD
Captopril—Orthostatic hypotension—Doxorubicin—liver cancer	0.000201	0.00333	CcSEcCtD
Captopril—Angina pectoris—Epirubicin—liver cancer	0.000201	0.00332	CcSEcCtD
Captopril—Rash—Sorafenib—liver cancer	0.0002	0.0033	CcSEcCtD
Captopril—Dermatitis—Sorafenib—liver cancer	0.0002	0.0033	CcSEcCtD
Captopril—CYP2D6—liver—liver cancer	0.000199	0.00212	CbGeAlD
Captopril—Headache—Sorafenib—liver cancer	0.000199	0.00328	CcSEcCtD
Captopril—Pancytopenia—Epirubicin—liver cancer	0.000196	0.00323	CcSEcCtD
Captopril—Muscular weakness—Doxorubicin—liver cancer	0.000195	0.00322	CcSEcCtD
Captopril—Neutropenia—Epirubicin—liver cancer	0.000193	0.00319	CcSEcCtD
Captopril—Pollakiuria—Epirubicin—liver cancer	0.00019	0.00315	CcSEcCtD
Captopril—Eosinophilia—Doxorubicin—liver cancer	0.000189	0.00312	CcSEcCtD
Captopril—Nausea—Sorafenib—liver cancer	0.000188	0.00311	CcSEcCtD
Captopril—Photosensitivity reaction—Epirubicin—liver cancer	0.000188	0.00311	CcSEcCtD
Captopril—Pancreatitis—Doxorubicin—liver cancer	0.000187	0.00309	CcSEcCtD
Captopril—Weight decreased—Epirubicin—liver cancer	0.000186	0.00308	CcSEcCtD
Captopril—Angina pectoris—Doxorubicin—liver cancer	0.000186	0.00307	CcSEcCtD
Captopril—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000182	0.00301	CcSEcCtD
Captopril—Pancytopenia—Doxorubicin—liver cancer	0.000181	0.00299	CcSEcCtD
Captopril—Renal failure—Epirubicin—liver cancer	0.000181	0.00299	CcSEcCtD
Captopril—Stomatitis—Epirubicin—liver cancer	0.000179	0.00296	CcSEcCtD
Captopril—Jaundice—Epirubicin—liver cancer	0.000179	0.00296	CcSEcCtD
Captopril—Neutropenia—Doxorubicin—liver cancer	0.000178	0.00295	CcSEcCtD
Captopril—Pollakiuria—Doxorubicin—liver cancer	0.000176	0.00291	CcSEcCtD
Captopril—Photosensitivity reaction—Doxorubicin—liver cancer	0.000174	0.00288	CcSEcCtD
Captopril—Weight decreased—Doxorubicin—liver cancer	0.000172	0.00285	CcSEcCtD
Captopril—Agranulocytosis—Epirubicin—liver cancer	0.000171	0.00283	CcSEcCtD
Captopril—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000169	0.00279	CcSEcCtD
Captopril—Renal failure—Doxorubicin—liver cancer	0.000167	0.00276	CcSEcCtD
Captopril—Stomatitis—Doxorubicin—liver cancer	0.000166	0.00274	CcSEcCtD
Captopril—Jaundice—Doxorubicin—liver cancer	0.000166	0.00274	CcSEcCtD
Captopril—Rhinitis—Epirubicin—liver cancer	0.000165	0.00273	CcSEcCtD
Captopril—Hepatitis—Epirubicin—liver cancer	0.000165	0.00273	CcSEcCtD
Captopril—Pharyngitis—Epirubicin—liver cancer	0.000164	0.00271	CcSEcCtD
Captopril—Agranulocytosis—Doxorubicin—liver cancer	0.000159	0.00262	CcSEcCtD
Captopril—Erythema multiforme—Epirubicin—liver cancer	0.000156	0.00258	CcSEcCtD
Captopril—Flushing—Epirubicin—liver cancer	0.000153	0.00253	CcSEcCtD
Captopril—Rhinitis—Doxorubicin—liver cancer	0.000153	0.00253	CcSEcCtD
Captopril—Hepatitis—Doxorubicin—liver cancer	0.000153	0.00252	CcSEcCtD
Captopril—Pharyngitis—Doxorubicin—liver cancer	0.000151	0.0025	CcSEcCtD
Captopril—Alopecia—Epirubicin—liver cancer	0.000146	0.00241	CcSEcCtD
Captopril—Erythema multiforme—Doxorubicin—liver cancer	0.000144	0.00239	CcSEcCtD
Captopril—ABCB1—liver—liver cancer	0.000143	0.00152	CbGeAlD
Captopril—Flushing—Doxorubicin—liver cancer	0.000142	0.00234	CcSEcCtD
Captopril—Tension—Epirubicin—liver cancer	0.000141	0.00233	CcSEcCtD
Captopril—Dysgeusia—Epirubicin—liver cancer	0.000141	0.00232	CcSEcCtD
Captopril—Nervousness—Epirubicin—liver cancer	0.000139	0.00231	CcSEcCtD
Captopril—ABCB1—Sorafenib—liver cancer	0.000137	0.321	CbGbCtD
Captopril—Vision blurred—Epirubicin—liver cancer	0.000135	0.00224	CcSEcCtD
Captopril—Alopecia—Doxorubicin—liver cancer	0.000135	0.00223	CcSEcCtD
Captopril—Ill-defined disorder—Epirubicin—liver cancer	0.000133	0.0022	CcSEcCtD
Captopril—Anaemia—Epirubicin—liver cancer	0.000133	0.00219	CcSEcCtD
Captopril—Tension—Doxorubicin—liver cancer	0.00013	0.00215	CcSEcCtD
Captopril—Dysgeusia—Doxorubicin—liver cancer	0.00013	0.00215	CcSEcCtD
Captopril—Malaise—Epirubicin—liver cancer	0.000129	0.00214	CcSEcCtD
Captopril—CYP2D6—Sorafenib—liver cancer	0.000129	0.302	CbGbCtD
Captopril—Nervousness—Doxorubicin—liver cancer	0.000129	0.00213	CcSEcCtD
Captopril—Syncope—Epirubicin—liver cancer	0.000129	0.00213	CcSEcCtD
Captopril—Palpitations—Epirubicin—liver cancer	0.000127	0.0021	CcSEcCtD
Captopril—Loss of consciousness—Epirubicin—liver cancer	0.000126	0.00209	CcSEcCtD
Captopril—Cough—Epirubicin—liver cancer	0.000125	0.00207	CcSEcCtD
Captopril—Vision blurred—Doxorubicin—liver cancer	0.000125	0.00207	CcSEcCtD
Captopril—Ill-defined disorder—Doxorubicin—liver cancer	0.000123	0.00204	CcSEcCtD
Captopril—Anaemia—Doxorubicin—liver cancer	0.000123	0.00203	CcSEcCtD
Captopril—Arthralgia—Epirubicin—liver cancer	0.000122	0.00202	CcSEcCtD
Captopril—Chest pain—Epirubicin—liver cancer	0.000122	0.00202	CcSEcCtD
Captopril—Myalgia—Epirubicin—liver cancer	0.000122	0.00202	CcSEcCtD
Captopril—Discomfort—Epirubicin—liver cancer	0.000121	0.002	CcSEcCtD
Captopril—Malaise—Doxorubicin—liver cancer	0.00012	0.00198	CcSEcCtD
Captopril—Dry mouth—Epirubicin—liver cancer	0.00012	0.00198	CcSEcCtD
Captopril—Syncope—Doxorubicin—liver cancer	0.000119	0.00197	CcSEcCtD
Captopril—Confusional state—Epirubicin—liver cancer	0.000118	0.00195	CcSEcCtD
Captopril—Palpitations—Doxorubicin—liver cancer	0.000117	0.00194	CcSEcCtD
Captopril—Anaphylactic shock—Epirubicin—liver cancer	0.000117	0.00194	CcSEcCtD
Captopril—Loss of consciousness—Doxorubicin—liver cancer	0.000117	0.00193	CcSEcCtD
Captopril—Cough—Doxorubicin—liver cancer	0.000116	0.00192	CcSEcCtD
Captopril—Shock—Epirubicin—liver cancer	0.000115	0.00191	CcSEcCtD
Captopril—Thrombocytopenia—Epirubicin—liver cancer	0.000115	0.0019	CcSEcCtD
Captopril—Tachycardia—Epirubicin—liver cancer	0.000114	0.00189	CcSEcCtD
Captopril—Myalgia—Doxorubicin—liver cancer	0.000113	0.00187	CcSEcCtD
Captopril—Arthralgia—Doxorubicin—liver cancer	0.000113	0.00187	CcSEcCtD
Captopril—Chest pain—Doxorubicin—liver cancer	0.000113	0.00187	CcSEcCtD
Captopril—Discomfort—Doxorubicin—liver cancer	0.000112	0.00185	CcSEcCtD
Captopril—Anorexia—Epirubicin—liver cancer	0.000112	0.00185	CcSEcCtD
Captopril—Dry mouth—Doxorubicin—liver cancer	0.000111	0.00183	CcSEcCtD
Captopril—Hypotension—Epirubicin—liver cancer	0.000109	0.00181	CcSEcCtD
Captopril—Confusional state—Doxorubicin—liver cancer	0.000109	0.00181	CcSEcCtD
Captopril—Anaphylactic shock—Doxorubicin—liver cancer	0.000108	0.00179	CcSEcCtD
Captopril—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000107	0.00176	CcSEcCtD
Captopril—Shock—Doxorubicin—liver cancer	0.000107	0.00176	CcSEcCtD
Captopril—Thrombocytopenia—Doxorubicin—liver cancer	0.000106	0.00175	CcSEcCtD
Captopril—Insomnia—Epirubicin—liver cancer	0.000106	0.00175	CcSEcCtD
Captopril—Tachycardia—Doxorubicin—liver cancer	0.000106	0.00175	CcSEcCtD
Captopril—Paraesthesia—Epirubicin—liver cancer	0.000105	0.00174	CcSEcCtD
Captopril—Dyspnoea—Epirubicin—liver cancer	0.000104	0.00173	CcSEcCtD
Captopril—Somnolence—Epirubicin—liver cancer	0.000104	0.00172	CcSEcCtD
Captopril—Anorexia—Doxorubicin—liver cancer	0.000103	0.00171	CcSEcCtD
Captopril—Dyspepsia—Epirubicin—liver cancer	0.000103	0.00171	CcSEcCtD
Captopril—Decreased appetite—Epirubicin—liver cancer	0.000102	0.00168	CcSEcCtD
Captopril—Hypotension—Doxorubicin—liver cancer	0.000101	0.00167	CcSEcCtD
Captopril—Fatigue—Epirubicin—liver cancer	0.000101	0.00167	CcSEcCtD
Captopril—Constipation—Epirubicin—liver cancer	0.0001	0.00166	CcSEcCtD
Captopril—Musculoskeletal discomfort—Doxorubicin—liver cancer	9.88e-05	0.00163	CcSEcCtD
Captopril—Insomnia—Doxorubicin—liver cancer	9.81e-05	0.00162	CcSEcCtD
Captopril—Paraesthesia—Doxorubicin—liver cancer	9.74e-05	0.00161	CcSEcCtD
Captopril—Dyspnoea—Doxorubicin—liver cancer	9.67e-05	0.0016	CcSEcCtD
Captopril—Feeling abnormal—Epirubicin—liver cancer	9.66e-05	0.0016	CcSEcCtD
Captopril—Somnolence—Doxorubicin—liver cancer	9.64e-05	0.00159	CcSEcCtD
Captopril—Gastrointestinal pain—Epirubicin—liver cancer	9.58e-05	0.00158	CcSEcCtD
Captopril—Dyspepsia—Doxorubicin—liver cancer	9.54e-05	0.00158	CcSEcCtD
Captopril—Decreased appetite—Doxorubicin—liver cancer	9.42e-05	0.00156	CcSEcCtD
Captopril—Fatigue—Doxorubicin—liver cancer	9.35e-05	0.00155	CcSEcCtD
Captopril—Constipation—Doxorubicin—liver cancer	9.27e-05	0.00153	CcSEcCtD
Captopril—Abdominal pain—Epirubicin—liver cancer	9.26e-05	0.00153	CcSEcCtD
Captopril—Body temperature increased—Epirubicin—liver cancer	9.26e-05	0.00153	CcSEcCtD
Captopril—Feeling abnormal—Doxorubicin—liver cancer	8.93e-05	0.00148	CcSEcCtD
Captopril—Gastrointestinal pain—Doxorubicin—liver cancer	8.87e-05	0.00147	CcSEcCtD
Captopril—Body temperature increased—Doxorubicin—liver cancer	8.57e-05	0.00142	CcSEcCtD
Captopril—Abdominal pain—Doxorubicin—liver cancer	8.57e-05	0.00142	CcSEcCtD
Captopril—Asthenia—Epirubicin—liver cancer	8.41e-05	0.00139	CcSEcCtD
Captopril—ABCB1—Doxorubicin—liver cancer	8.31e-05	0.194	CbGbCtD
Captopril—Pruritus—Epirubicin—liver cancer	8.29e-05	0.00137	CcSEcCtD
Captopril—Diarrhoea—Epirubicin—liver cancer	8.02e-05	0.00133	CcSEcCtD
Captopril—CYP2D6—Doxorubicin—liver cancer	7.83e-05	0.183	CbGbCtD
Captopril—Asthenia—Doxorubicin—liver cancer	7.78e-05	0.00129	CcSEcCtD
Captopril—Dizziness—Epirubicin—liver cancer	7.75e-05	0.00128	CcSEcCtD
Captopril—Pruritus—Doxorubicin—liver cancer	7.67e-05	0.00127	CcSEcCtD
Captopril—Vomiting—Epirubicin—liver cancer	7.45e-05	0.00123	CcSEcCtD
Captopril—Diarrhoea—Doxorubicin—liver cancer	7.42e-05	0.00123	CcSEcCtD
Captopril—Rash—Epirubicin—liver cancer	7.39e-05	0.00122	CcSEcCtD
Captopril—Dermatitis—Epirubicin—liver cancer	7.38e-05	0.00122	CcSEcCtD
Captopril—Headache—Epirubicin—liver cancer	7.34e-05	0.00121	CcSEcCtD
Captopril—Dizziness—Doxorubicin—liver cancer	7.17e-05	0.00119	CcSEcCtD
Captopril—Nausea—Epirubicin—liver cancer	6.96e-05	0.00115	CcSEcCtD
Captopril—Vomiting—Doxorubicin—liver cancer	6.89e-05	0.00114	CcSEcCtD
Captopril—Rash—Doxorubicin—liver cancer	6.84e-05	0.00113	CcSEcCtD
Captopril—Dermatitis—Doxorubicin—liver cancer	6.83e-05	0.00113	CcSEcCtD
Captopril—Headache—Doxorubicin—liver cancer	6.79e-05	0.00112	CcSEcCtD
Captopril—Nausea—Doxorubicin—liver cancer	6.44e-05	0.00106	CcSEcCtD
Captopril—F2—GPCR downstream signaling—PIK3CG—liver cancer	1.55e-05	0.000147	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—IGF2—liver cancer	1.53e-05	0.000146	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—RAF1—liver cancer	1.48e-05	0.000141	CbGpPWpGaD
Captopril—F2—Hemostasis—VEGFA—liver cancer	1.46e-05	0.000139	CbGpPWpGaD
Captopril—ALB—Hemostasis—PRKCE—liver cancer	1.46e-05	0.000139	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	1.46e-05	0.000139	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—PIK3CB—liver cancer	1.44e-05	0.000137	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—GGT1—liver cancer	1.44e-05	0.000137	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—CSF2—liver cancer	1.43e-05	0.000136	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—H2AFX—liver cancer	1.41e-05	0.000134	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—PIK3CG—liver cancer	1.41e-05	0.000134	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—ALB—liver cancer	1.4e-05	0.000134	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—CYCS—liver cancer	1.4e-05	0.000133	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—HRAS—liver cancer	1.4e-05	0.000133	CbGpPWpGaD
Captopril—ALB—Hemostasis—ABL1—liver cancer	1.39e-05	0.000132	CbGpPWpGaD
Captopril—ALB—Hemostasis—IGF2—liver cancer	1.39e-05	0.000132	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—PIK3CD—liver cancer	1.36e-05	0.000129	CbGpPWpGaD
Captopril—F2—Hemostasis—TGFB1—liver cancer	1.34e-05	0.000128	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—IL6—liver cancer	1.34e-05	0.000127	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	1.33e-05	0.000127	CbGpPWpGaD
Captopril—ALB—Metabolism—CPT1B—liver cancer	1.33e-05	0.000127	CbGpPWpGaD
Captopril—ALB—Metabolism—GLUL—liver cancer	1.33e-05	0.000127	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—IL2—liver cancer	1.33e-05	0.000126	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—CTNNB1—liver cancer	1.31e-05	0.000124	CbGpPWpGaD
Captopril—ALB—Hemostasis—HGF—liver cancer	1.31e-05	0.000124	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	1.31e-05	0.000124	CbGpPWpGaD
Captopril—ALB—Hemostasis—CSF2—liver cancer	1.29e-05	0.000123	CbGpPWpGaD
Captopril—ALB—Metabolism—NR1H4—liver cancer	1.29e-05	0.000122	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—TERT—liver cancer	1.28e-05	0.000121	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	1.27e-05	0.000121	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	1.27e-05	0.000121	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—RAF1—liver cancer	1.27e-05	0.000121	CbGpPWpGaD
Captopril—ALB—Metabolism—GSTA3—liver cancer	1.26e-05	0.00012	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	1.26e-05	0.00012	CbGpPWpGaD
Captopril—F2—Signaling Pathways—PRKCE—liver cancer	1.25e-05	0.000119	CbGpPWpGaD
Captopril—F2—Hemostasis—KRAS—liver cancer	1.25e-05	0.000118	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—PIK3CD—liver cancer	1.24e-05	0.000117	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—AKT1—liver cancer	1.23e-05	0.000117	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	1.23e-05	0.000117	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—CYCS—liver cancer	1.23e-05	0.000117	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—HMOX1—liver cancer	1.22e-05	0.000116	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	1.2e-05	0.000114	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—PIK3CB—liver cancer	1.19e-05	0.000113	CbGpPWpGaD
Captopril—F2—Signaling Pathways—IGF2—liver cancer	1.18e-05	0.000113	CbGpPWpGaD
Captopril—ABCB1—Metabolism—CPT1B—liver cancer	1.17e-05	0.000111	CbGpPWpGaD
Captopril—ABCB1—Metabolism—GLUL—liver cancer	1.17e-05	0.000111	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—KDR—liver cancer	1.17e-05	0.000111	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—MAPK14—liver cancer	1.16e-05	0.00011	CbGpPWpGaD
Captopril—ALB—Metabolism—GSTA4—liver cancer	1.16e-05	0.00011	CbGpPWpGaD
Captopril—F2—Hemostasis—PIK3CA—liver cancer	1.14e-05	0.000109	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—ESR1—liver cancer	1.14e-05	0.000108	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	1.13e-05	0.000107	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—VEGFA—liver cancer	1.13e-05	0.000107	CbGpPWpGaD
Captopril—ALB—Metabolism—GSTA2—liver cancer	1.13e-05	0.000107	CbGpPWpGaD
Captopril—ABCB1—Metabolism—NR1H4—liver cancer	1.13e-05	0.000107	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—F2—liver cancer	1.12e-05	0.000107	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	1.11e-05	0.000106	CbGpPWpGaD
Captopril—ABCB1—Metabolism—GSTA3—liver cancer	1.11e-05	0.000105	CbGpPWpGaD
Captopril—F2—Hemostasis—TP53—liver cancer	1.11e-05	0.000105	CbGpPWpGaD
Captopril—F2—Signaling Pathways—CSF2—liver cancer	1.11e-05	0.000105	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—RAF1—liver cancer	1.1e-05	0.000105	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—GLUL—liver cancer	1.1e-05	0.000105	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—CPT1B—liver cancer	1.1e-05	0.000105	CbGpPWpGaD
Captopril—F2—Signaling Pathways—H2AFX—liver cancer	1.09e-05	0.000104	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—IL2—liver cancer	1.09e-05	0.000104	CbGpPWpGaD
Captopril—ALB—Metabolism—GSTA1—liver cancer	1.09e-05	0.000103	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—PIK3CB—liver cancer	1.08e-05	0.000102	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—PIK3CG—liver cancer	1.08e-05	0.000102	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—APC—liver cancer	1.08e-05	0.000102	CbGpPWpGaD
Captopril—ALB—Metabolism—NAT2—liver cancer	1.07e-05	0.000102	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—HMOX1—liver cancer	1.07e-05	0.000101	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—NR1H4—liver cancer	1.06e-05	0.000101	CbGpPWpGaD
Captopril—F2—Hemostasis—HRAS—liver cancer	1.06e-05	0.000101	CbGpPWpGaD
Captopril—ALB—Hemostasis—MAPK14—liver cancer	1.05e-05	9.96e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—GSTA3—liver cancer	1.04e-05	9.92e-05	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—TGFB1—liver cancer	1.03e-05	9.84e-05	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—PPARA—liver cancer	1.03e-05	9.82e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—ALDOB—liver cancer	1.03e-05	9.79e-05	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	1.02e-05	9.71e-05	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	1.02e-05	9.69e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—F2—liver cancer	1.02e-05	9.65e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—GSTA4—liver cancer	1.01e-05	9.63e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—BRAF—liver cancer	1.01e-05	9.61e-05	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—IL2—liver cancer	9.89e-06	9.4e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—GSTA2—liver cancer	9.87e-06	9.38e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—TERT—liver cancer	9.85e-06	9.37e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—CRABP1—liver cancer	9.83e-06	9.34e-05	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—PPARA—liver cancer	9.82e-06	9.34e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—PIK3CG—liver cancer	9.72e-06	9.24e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—GSTA4—liver cancer	9.54e-06	9.07e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—GSTA1—liver cancer	9.52e-06	9.05e-05	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	9.51e-06	9.05e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—PIK3CD—liver cancer	9.45e-06	8.99e-05	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	9.44e-06	8.97e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—NAT2—liver cancer	9.41e-06	8.95e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—SERPINE1—liver cancer	9.35e-06	8.89e-05	CbGpPWpGaD
Captopril—F2—Hemostasis—AKT1—liver cancer	9.34e-06	8.88e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—GSTA2—liver cancer	9.3e-06	8.84e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—ALDOB—liver cancer	9.02e-06	8.58e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—KDR—liver cancer	9.01e-06	8.57e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—GSTA1—liver cancer	8.97e-06	8.53e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—MAPK14—liver cancer	8.95e-06	8.51e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—NAT2—liver cancer	8.87e-06	8.43e-05	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	8.85e-06	8.41e-05	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—PIK3CA—liver cancer	8.81e-06	8.37e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—ESR1—liver cancer	8.78e-06	8.35e-05	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	8.67e-06	8.24e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—CRABP1—liver cancer	8.61e-06	8.18e-05	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—PPARA—liver cancer	8.61e-06	8.18e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—HPGDS—liver cancer	8.59e-06	8.16e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—PIK3CD—liver cancer	8.54e-06	8.12e-05	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—PPARG—liver cancer	8.54e-06	8.12e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—ALDOB—liver cancer	8.5e-06	8.08e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—SERPINE1—liver cancer	8.45e-06	8.03e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—RAF1—liver cancer	8.44e-06	8.02e-05	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	8.39e-06	7.97e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—PIK3CG—liver cancer	8.3e-06	7.89e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—APC—liver cancer	8.3e-06	7.89e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—MTOR—liver cancer	8.24e-06	7.83e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—PIK3CB—liver cancer	8.24e-06	7.83e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—CRABP1—liver cancer	8.11e-06	7.71e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—BRAF—liver cancer	7.8e-06	7.42e-05	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	7.78e-06	7.39e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—CDKN1B—liver cancer	7.73e-06	7.35e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—PSMD10—liver cancer	7.65e-06	7.28e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—PSMA4—liver cancer	7.65e-06	7.28e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—RAF1—liver cancer	7.63e-06	7.25e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—CASP3—liver cancer	7.58e-06	7.21e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—IL2—liver cancer	7.57e-06	7.19e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—HPGDS—liver cancer	7.52e-06	7.15e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—GOT2—liver cancer	7.45e-06	7.08e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—PIK3CB—liver cancer	7.45e-06	7.08e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—CCND1—liver cancer	7.38e-06	7.01e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—JUN—liver cancer	7.36e-06	7e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—CTNNB1—liver cancer	7.3e-06	6.95e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—PIK3CD—liver cancer	7.3e-06	6.94e-05	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—PIK3CA—liver cancer	7.23e-06	6.87e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—SERPINE1—liver cancer	7.22e-06	6.86e-05	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—AKT1—liver cancer	7.19e-06	6.84e-05	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—KRAS—liver cancer	7.15e-06	6.79e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—CDKN1A—liver cancer	7.14e-06	6.78e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—HPGDS—liver cancer	7.09e-06	6.74e-05	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	7.08e-06	6.73e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—CYP2E1—liver cancer	7e-06	6.66e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—MAPK8—liver cancer	6.96e-06	6.62e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—IL2—liver cancer	6.84e-06	6.5e-05	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	6.78e-06	6.44e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—PSMA4—liver cancer	6.71e-06	6.38e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—PSMD10—liver cancer	6.71e-06	6.38e-05	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—RAF1—liver cancer	6.6e-06	6.28e-05	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—PIK3CA—liver cancer	6.56e-06	6.24e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—CYCS—liver cancer	6.55e-06	6.23e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—GOT2—liver cancer	6.52e-06	6.2e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—RAF1—liver cancer	6.52e-06	6.19e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—VEGFA—liver cancer	6.43e-06	6.11e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—GOT1—liver cancer	6.43e-06	6.11e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—GGT1—liver cancer	6.43e-06	6.11e-05	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	6.4e-06	6.08e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—STAT3—liver cancer	6.37e-06	6.05e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—MTOR—liver cancer	6.36e-06	6.05e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—PIK3CB—liver cancer	6.36e-06	6.05e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—PSMA4—liver cancer	6.32e-06	6.01e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—PSMD10—liver cancer	6.32e-06	6.01e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—GOT2—liver cancer	6.15e-06	5.85e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—CYP2E1—liver cancer	6.13e-06	5.83e-05	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—HRAS—liver cancer	6.07e-06	5.77e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—CDKN1B—liver cancer	5.97e-06	5.68e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—MYC—liver cancer	5.92e-06	5.63e-05	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—AKT1—liver cancer	5.91e-06	5.61e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—TGFB1—liver cancer	5.9e-06	5.61e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—CASP3—liver cancer	5.85e-06	5.56e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—IL2—liver cancer	5.84e-06	5.55e-05	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—IL6—liver cancer	5.81e-06	5.53e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—VEGFA—liver cancer	5.81e-06	5.52e-05	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	5.78e-06	5.5e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—CYP2E1—liver cancer	5.78e-06	5.5e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—GSTP1—liver cancer	5.77e-06	5.49e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—CYCS—liver cancer	5.74e-06	5.46e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—CCND1—liver cancer	5.7e-06	5.41e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—HMOX1—liver cancer	5.69e-06	5.41e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—JUN—liver cancer	5.68e-06	5.4e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—CTNNB1—liver cancer	5.64e-06	5.36e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—GGT1—liver cancer	5.63e-06	5.35e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—GOT1—liver cancer	5.63e-06	5.35e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—MMP9—liver cancer	5.53e-06	5.26e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—CDKN1A—liver cancer	5.51e-06	5.24e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—KRAS—liver cancer	5.47e-06	5.2e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—CYCS—liver cancer	5.41e-06	5.14e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—MAPK8—liver cancer	5.38e-06	5.11e-05	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—AKT1—liver cancer	5.36e-06	5.1e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—TGFB1—liver cancer	5.33e-06	5.07e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—GOT1—liver cancer	5.31e-06	5.05e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—GGT1—liver cancer	5.31e-06	5.05e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—GSTM1—liver cancer	5.31e-06	5.04e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—GSTP1—liver cancer	5.06e-06	4.81e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—CYP1A1—liver cancer	5.03e-06	4.78e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—PIK3CA—liver cancer	5.02e-06	4.78e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—HMOX1—liver cancer	4.99e-06	4.74e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—VEGFA—liver cancer	4.97e-06	4.72e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—KRAS—liver cancer	4.94e-06	4.7e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—STAT3—liver cancer	4.92e-06	4.67e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—TP53—liver cancer	4.86e-06	4.62e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—GSTP1—liver cancer	4.77e-06	4.53e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—HMOX1—liver cancer	4.7e-06	4.47e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—MTHFR—liver cancer	4.69e-06	4.46e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—GSTM1—liver cancer	4.65e-06	4.42e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—HRAS—liver cancer	4.65e-06	4.42e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—PPARA—liver cancer	4.6e-06	4.37e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—MYC—liver cancer	4.57e-06	4.34e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—TGFB1—liver cancer	4.56e-06	4.33e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—PIK3CA—liver cancer	4.54e-06	4.32e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—IL6—liver cancer	4.45e-06	4.23e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—CYP1A1—liver cancer	4.41e-06	4.19e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—TP53—liver cancer	4.39e-06	4.17e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—GSTM1—liver cancer	4.38e-06	4.16e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—KRAS—liver cancer	4.22e-06	4.01e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—HRAS—liver cancer	4.2e-06	3.99e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—CYP1A1—liver cancer	4.15e-06	3.95e-05	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.13e-06	3.93e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—MTHFR—liver cancer	4.11e-06	3.91e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—AKT1—liver cancer	4.1e-06	3.9e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—PPARA—liver cancer	4.03e-06	3.83e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—PIK3CG—liver cancer	3.94e-06	3.75e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—PIK3CA—liver cancer	3.88e-06	3.69e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—MTHFR—liver cancer	3.87e-06	3.68e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—PPARG—liver cancer	3.8e-06	3.62e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—PPARA—liver cancer	3.8e-06	3.61e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—TP53—liver cancer	3.75e-06	3.57e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—AKT1—liver cancer	3.71e-06	3.53e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—HRAS—liver cancer	3.59e-06	3.41e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—PIK3CD—liver cancer	3.46e-06	3.29e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—PIK3CG—liver cancer	3.45e-06	3.28e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—IL6—liver cancer	3.43e-06	3.26e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—PPARG—liver cancer	3.33e-06	3.17e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—PIK3CG—liver cancer	3.25e-06	3.09e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—AKT1—liver cancer	3.17e-06	3.01e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—PPARG—liver cancer	3.14e-06	2.98e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—PIK3CD—liver cancer	3.03e-06	2.89e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—PIK3CB—liver cancer	3.02e-06	2.87e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—ALB—liver cancer	3e-06	2.85e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—PIK3CD—liver cancer	2.86e-06	2.72e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—ALB—liver cancer	2.82e-06	2.68e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—PIK3CB—liver cancer	2.64e-06	2.51e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—PIK3CB—liver cancer	2.49e-06	2.37e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—PIK3CA—liver cancer	1.84e-06	1.75e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—PIK3CA—liver cancer	1.61e-06	1.53e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—PIK3CA—liver cancer	1.52e-06	1.44e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—AKT1—liver cancer	1.5e-06	1.43e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—AKT1—liver cancer	1.32e-06	1.25e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—AKT1—liver cancer	1.24e-06	1.18e-05	CbGpPWpGaD
